Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV RIDGEFIELD, Conn.
http://www.biospace.com/news_story.aspx?StoryID=314123&full=1
http://www.biospace.com/news_story.aspx?StoryID=314123&full=1
No comments:
Post a Comment